These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9326197)

  • 1. Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation.
    Ritter M; Thiede C; Schäkel U; Schmidt M; Alpen B; Pascheberg U; Mohr B; Ehninger G; Neubauer A
    Br J Haematol; 1997 Sep; 98(4):969-72. PubMed ID: 9326197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML.
    Evans PA; Short MA; Jack AS; Norfolk DR; Child JA; Shiach CR; Davies F; Tobal K; Liu Yin JA; Morgan GJ
    Leukemia; 1997 Mar; 11(3):364-9. PubMed ID: 9067575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
    Dissing M; Le Beau MM; Pedersen-Bjergaard J
    J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.
    Tobal K; Johnson PR; Saunders MJ; Harrison CJ; Liu Yin JA
    Br J Haematol; 1995 Sep; 91(1):104-8. PubMed ID: 7577615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
    Marcucci G; Caligiuri MA; Döhner H; Archer KJ; Schlenk RF; Döhner K; Maghraby EA; Bloomfield CD
    Leukemia; 2001 Jul; 15(7):1072-80. PubMed ID: 11455976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and laboratory features of pediatric acute myeloid leukemia with inversion of chromosome 16].
    He YX; Xue YQ; Wang HY; Yang NC; Shao XJ; Xu J; Ji ZH; Huang YP; Ding YF; Hu SY
    Zhonghua Er Ke Za Zhi; 2012 Aug; 50(8):593-7. PubMed ID: 23158736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
    Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
    Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
    Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
    Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
    Monma F; Nishii K; Shiga J; Sugahara H; Lorenzo F; Watanabe Y; Kawakami K; Hosokai N; Yamamori S; Katayama N; Shiku H
    Leuk Res; 2007 Apr; 31(4):471-6. PubMed ID: 17052753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
    Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients.
    Mancini M; Cedrone M; Diverio D; Emanuel B; Stul M; Vranckx H; Brama M; De Cuia MR; Nanni M; Fazi F; Mecucci C; Alimena G; Hagemeijer A
    Leukemia; 2000 Mar; 14(3):364-8. PubMed ID: 10720127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
    Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
    Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of minimally differentiated acute myeloid leukemia with chromosome 16 inversion.
    Sotomatsu M; Ogawa C; Shimoda M; Matsui A; Nakazawa S; Eguchi M; Morikawa A
    Leuk Lymphoma; 1997 Jan; 24(3-4):319-25. PubMed ID: 9156661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion.
    van der Reijden BA; Simons A; Luiten E; van der Poel SC; Hogenbirk PE; Tönnissen E; Valk PJ; Löwenberg B; De Greef GE; Breuning MH; Jansen JH
    Br J Haematol; 2002 Aug; 118(2):411-8. PubMed ID: 12139724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
    Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
    Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of CBFbeta/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics.
    Costello R; Sainty D; Lecine P; Cusenier A; Mozziconacci MJ; Arnoulet C; Maraninchi D; Gastaut JA; Imbert J; Lafage-Pochitaloff M; Gabert J
    Leukemia; 1997 May; 11(5):644-50. PubMed ID: 9180286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification.
    Hébert J; Cayuela JM; Daniel MT; Berger R; Sigaux F
    Blood; 1994 Oct; 84(7):2291-6. PubMed ID: 7919348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.